Laxon Drugs Profile
Key Indicators
- Authorised Capital ₹ 7.50 M
- Paid Up Capital ₹ 5.04 M
- Company Age 32 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 10.27 Cr
- Satisfied Charges ₹ 2.45 M
- Revenue Growth -43.96%
- Profit Growth 26.40%
- Ebitda -6.20%
- Net Worth 17.47%
- Total Assets 54.99%
About Laxon Drugs
Laxon Drugs Private Limited (LDPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 02 November 1992 and has a history of 32 years and three months. Its registered office is in Chandigarh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 7.50 M and a paid-up capital of Rs 5.04 M.
The company currently has active open charges totaling ₹10.27 Cr. The company has closed loans amounting to ₹2.45 M, as per Ministry of Corporate Affairs (MCA) records.
Tanu Soni and Ashwani Soni serve as directors at the Company.
Company Details
-
Location
Chandigarh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U51397CH1992PTC012679
-
Company No.
012679
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
02 Nov 1992
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Chandigarh
Industry
Who are the key members and board of directors at Laxon Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Tanu Soni
|
Director | 02-Nov-1992 | Current |
|
Ashwani Soni
|
Director | 14-Nov-2022 | Current |
Financial Performance of Laxon Drugs.
Laxon Drugs Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 43.96% decrease. The company also saw a substantial improvement in profitability, with a 26.4% increase in profit. The company's net worth Soared by an impressive increase of 17.47%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Laxon Drugs?
In 2021, Laxon Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹102.70 M
₹2.45 M
Charges Breakdown by Lending Institutions
- Punjab National Bank : 7.70 Cr
- Others : 2.57 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 22 Jul 2020 | Others | ₹0.70 M | Open |
| 11 Jun 2015 | Punjab National Bank | ₹1.10 M | Open |
| 22 Dec 2011 | Punjab National Bank | ₹9.50 M | Open |
| 18 Feb 2009 | Others | ₹2.50 Cr | Open |
| 18 Feb 2009 | Punjab National Bank | ₹1.20 Cr | Open |
How Many Employees Work at Laxon Drugs?
Laxon Drugs has a workforce of 6 employees as of Mar 23, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Laxon Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Laxon Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
